Zetagen Therapeutics announced it has closed a $12,908,000 Series B1 financing round that was fully oversubscribed, reflecting strong investor interest in the company’s intratumoral therapeutic platform targeting primary and metastatic breast cancer. The round was led by private investors, including JSTAR Capital Investments, signaling growing confidence in the company’s Phase 2a clinical results and expanding intellectual property portfolio.
The company will use the new funding to continue advancing ZetaMet, its lead candidate for the treatment of metastatic breast cancer in bone, toward commercialization. The financing will also accelerate clinical development for ZetaMast, a therapy targeting breast cancer liver metastases, and support preclinical work and GMP manufacturing for ZetaPrime, a neo-adjuvant candidate aimed at reducing off-target toxicity in primary HR+ breast cancer.
ZetaMet recently completed a Phase 2a clinical trial at the University of British Columbia showing a Complete Response in treated lesions, full bone regeneration, and no skeletal-related events following a single intratumoral injection. Preliminary results will be presented at the upcoming San Antonio Breast Cancer Symposium (SABCS). ZetaMast has demonstrated encouraging preclinical results published in PLOS ONE, including reduced liver tumor burden and improved survival. ZetaPrime’s in-vivo results showed improved tumor suppression and survival compared to Tamoxifen and Verzenio in a mammary fat pad mouse model, with data also set to be shared at SABCS.
The company now holds more than 70 issued patents—including Composition-of-Matter patents covering ZetaMet, ZetaMast, and ZetaPrime—reflecting progress in strengthening its global IP position. Zetagen will also participate in the 2025 San Antonio Breast Cancer Symposium and the 2026 JP Morgan Healthcare Conference as it expands visibility of its clinical pipeline.
KEY QUOTES
“The strong demand in our Series B1 round highlights the promise of our Phase 2a clinical data for ZetaMet in treating metastatic breast cancer to bone. At the core of these encouraging results is our discovery of a novel molecular pathway—triggered by our compounds activating a conserved nuclear receptor—which enables promising predictability in dosing and outcomes from bench to bedside.”
Joe C. Loy, CEO, Zetagen Therapeutics
